The maximum response (18.2%) was in patients with mismatch repair deficiency/high microsatellite instability (MSI-H) treated with anti-PD1 (Programmed cell death protein 1) (5); however, such tumors constitute less than one percent of PDA (42). The gene discussed is PDCD1; the disease is Patent ductus arteriosus.